Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
- Authors: Gorbunova V.A1, Kolyadina I.V1, Kovalenko E.I1, Manziuk L.V1, Artamonova E.V1, Zhukova L.G2, Bolotina L.V3, Semiglazova T.I.4, Manikhas A.G5, Raevskaia N.A5, Itkin I.M5, Filonenko D.V6, Zhilyaeva L.A7, Gol'dberg V.E8, Popova N.O8, Ponomarenko D.M9, Shikina V.E10, Suslova I.R11, Romanchuk O.V11, Kozlov D.V12, Rzaev A.S12, Marfutov V.V13, Andreiashkina I.I13, Vladimirova L.I14, Mitashok I.S14, Tikhanovskaia N.M14, Karabina E.V15, Mukhametshina G.Z16, Khasanova A.I16, Safina S.Z16, Shaidorov M.V17, Morozov D.A17, Prokof'eva E.P18, Kramskaia L.V19, Karandeeva T.V19, Evstigneeva I.V20, Ovchinnikova E.G21, Klement'eva T.P21, Khrupalo O.V12, Tiuvinova E.V22, Sherstnev V.M23, Chernov I.S23, Kolokolov D.D.24, Gaisina E.A25, Levchenko N.V26, Chubenko V.A26, Povyshev A.I.27, Iudina I.V28, Vorotilina L.V28, Andreeva T.V29, Tumanian G.S30, Koziakov A.E31, Gil'mutdinova L.A32, Osipov M.A33, Shatokhina A.S34, Vazhenina A.A35, Chichkanova A.S36, Vladimirov V.I37, Ivanov A.N38, Belokhvostova A.S39, Cherniakova E.M39, Tul'china E.A40, Maklashova S.A40, Shkodenko O.N41, Kostalanova I.V42, Tarasova A.V43, Kuz'mina E.S44
-
Affiliations:
- N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
- A.S.Loginov Moscow Clinical Scientific Practical Center of the Department of Health of Moscow
- P.A.Herzen Moscow Research Institute of Oncology - branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
- N.N.Petrov National Medical Research Center of Oncology
- City Clinical Oncology Dispensary
- Moscow City Oncology Hospital №62 of the Department of Health of Moscow
- Kursk Regional Clinical Oncology Center
- Research Institute of Oncology of the Tomsk National Research Medical Center of the Russian Academy of Sciences
- Regional Oncology Center
- Moscow Regional Oncological Dispensary
- Oncologic Dispensary №4
- Diagnostic Clinical Center №1
- A.S.Loginov Moscow Clinical Scientific Practical Center
- Rostov Research Institute of Oncology
- Tula Regional Oncologic Dispensary
- Republican Clinical Oncology Dispensary
- N.N.Blokhin National Medical Research Center of Oncology
- Penza Regional Oncology Center
- D.D.Pletnev City Clinical Hospital, a separate division "Oncological Dispensary"
- Tver Regional Clinical Oncology Dispensary
- Nizhny Novgorod Regional Clinical Oncology Dispensary
- City Polyclinic №201
- Oncologic Dispensary №5
- City Polyclinic №195
- "Medical City"
- Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care
- District Clinical Hospital
- Clinical Oncologic Dispensary
- Smolensk Regional Oncological Dispensary
- Primorsky Regional Oncology Center
- Novosibirsk Regional Clinical Oncologic Dispensary
- Regional Clinical Center of Oncology
- Leningrad Regional Oncological Dispensary
- Clinical Oncology Dispensary №1
- Medical Center "Sunrise Clinic"
- Privolzhskii District Medical Center
- Pyatigorsk Interdistrict Oncologic Dispensary
- Republican Clinical Oncologic Dispensary
- Republican Oncology Center
- Bryansk Regional Oncological Center
- Stavropol Regional Clinical Oncology Dispensary
- Samara Regional Clinical Oncology Dispensary
- Tolyatti City Clinical Hospital №5
- Salekhard District Clinical Hospital
- Issue: Vol 21, No 1 (2019)
- Pages: 12-23
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/33502
- DOI: https://doi.org/10.26442/18151434.2019.1.190250
- ID: 33502
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Vera A Gorbunova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation
Email: veragorbounova@mail.ru
MD, Ph.D, Professor, Leading Researcher in the Department of Chemotherapy 23, Kashirskoe h., Moscow, 115478, Russian Federation
Irina V Kolyadina
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationMD, Ph.D, Leading Researcher, Professor in the Department of Oncology and Palliative Medicine 23, Kashirskoe h., Moscow, 115478, Russian Federation
Elena I Kovalenko
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationCand. Sci. (Med.), Researcher in the Department of Chemotherapy 23, Kashirskoe h., Moscow, 115478, Russian Federation
Liudmila V Manziuk
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationMD, Ph.D, Professor, Leading Researcher in the Department of Outpatient Chemotherapy 23, Kashirskoe h., Moscow, 115478, Russian Federation
Elena V Artamonova
N.N.Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian FederationMD, Ph.D, Head of the Department of Chemotherapy 23, Kashirskoe h., Moscow, 115478, Russian Federation
Liudmila G Zhukova
A.S.Loginov Moscow Clinical Scientific Practical Center of the Department of Health of MoscowMD, Ph.D, Professor of RAS, Deputy Director 86, Entuziastov h., Moscow, 111123, Russian Federation
Larisa V Bolotina
P.A.Herzen Moscow Research Institute of Oncology - branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian FederationMD, Ph.D, Head of the Department of Chemotherapy 3, 2nd Botkinskii av., Moscow, 125284, Russian Federation
Tat'iana Iu Semiglazova
N.N.Petrov National Medical Research Center of OncologyMD, Ph.D, Professor, Head of the Department of Innovative Methods for Therapeutic Oncology and Rehabilitation 68, Pesochnyi, Leningradskaia st., Saint Petersburg, 197758, Russian Federation
Aleksei G Manikhas
City Clinical Oncology DispensaryMD, Ph.D, Head of the Department of Oncosurgery (Mammology) No.1 56, Veteranov av., Saint Petersburg, 198255, Russian Federation
Natal'ia A Raevskaia
City Clinical Oncology DispensaryHead of the Department of Oncology No.10 56, Veteranov av., Saint Petersburg, 198255, Russian Federation
Il'ia M Itkin
City Clinical Oncology DispensaryCand. Sci. (Med.), Oncologist of the Department of Oncology No.10 56, Veteranov av., Saint Petersburg, 198255, Russian Federation
Dmitrii V Filonenko
Moscow City Oncology Hospital №62 of the Department of Health of MoscowCand. Sci. (Med.), Oncologist of Day Patient Department No.1 6, Staropetrovsky av., Moscow, 125130, Russian Federation
Larisa A Zhilyaeva
Kursk Regional Clinical Oncology CenterHead of the Department of Outpatient Chemotherapy 20, Pirogov st., Kursk, 305035, Russian Federation
Viktor E Gol'dberg
Research Institute of Oncology of the Tomsk National Research Medical Center of the Russian Academy of SciencesMD, Ph.D, Professor, Honored Scientist of the RF, Head of the Department of Chemotherapy 5, Kooperativnyi l., Tomsk, 634009, Russian Federation
Natal'ia O Popova
Research Institute of Oncology of the Tomsk National Research Medical Center of the Russian Academy of SciencesCand. Sci. (Med.), Senior Researcher of the Department of Chemotherapy 5, Kooperativnyi l., Tomsk, 634009, Russian Federation
Dmitrii M Ponomarenko
Regional Oncology CenterCand. Sci. (Med.), High Level Certificate Physician, Head of the Department of Chemotherapy 32, Frunze st., Irkutsk, 664035, Russian Federation
Valentina E Shikina
Moscow Regional Oncological DispensaryHead of Day Patient Department
Irina R Suslova
Oncologic Dispensary №4ad of Day Patient Department
Olga V Romanchuk
Oncologic Dispensary №4Oncologist
Dmitrii V Kozlov
Diagnostic Clinical Center №1Cand. Sci. (Med.), Head of the Department of Oncology the Division No.5
Ali-Dzarakhmat S Rzaev
Diagnostic Clinical Center №1Cand. Sci. (Med.), Oncologist of the Division No.5
Vasilii V Marfutov
A.S.Loginov Moscow Clinical Scientific Practical CenterOncologist
Irina I Andreiashkina
A.S.Loginov Moscow Clinical Scientific Practical CenterMD, Ph.D, Deputy External Expert-Oncologist of the Department of Health of Moscow, Leading Researcher
Liubov' I Vladimirova
Rostov Research Institute of OncologyMD, Ph.D, Professor, Head of the Department of Antitumor Therapy No.1
Irina S Mitashok
Rostov Research Institute of OncologyHead of the Department of Antitumor Therapy No.2
Natal'ia M Tikhanovskaia
Rostov Research Institute of Oncologyhemotherapist of the Department of Antitumor Therapy No.1
Elena V Karabina
Tula Regional Oncologic DispensaryHead of the Department of Antitumor Therapy
Guzel' Z Mukhametshina
Republican Clinical Oncology DispensaryCand. Sci. (Med.), Head of the Department of Chemotherapy No.1
Al'fiia I Khasanova
Republican Clinical Oncology DispensaryCand. Sci. (Med.), Head of Day Patient Department No.2
Sufiia Z Safina
Republican Clinical Oncology DispensaryCand. Sci. (Med.), Head of the Department of Chemotherapy No.3
Mikhail V Shaidorov
N.N.Blokhin National Medical Research Center of OncologyResident Doctor of the Department of Oncology and Palliative Medicine
Dmitrii A Morozov
N.N.Blokhin National Medical Research Center of OncologyResident Doctor of the Department of Oncology and Palliative Medicine
Elena P Prokof'eva
Penza Regional Oncology CenterHead of Day Patient Chemotherapy Department
Liudmila V Kramskaia
D.D.Pletnev City Clinical Hospital, a separate division "Oncological Dispensary"Oncologist, Head of the Department of Oncology No.2
Tat'iana V Karandeeva
D.D.Pletnev City Clinical Hospital, a separate division "Oncological Dispensary"Oncologist
Irina V Evstigneeva
Tver Regional Clinical Oncology DispensaryHead of the Dispensary Department
Elena G Ovchinnikova
Nizhny Novgorod Regional Clinical Oncology DispensaryCand. Sci. (Med.), Head of the Department of Chemotherapy
Tat'iana P Klement'eva
Nizhny Novgorod Regional Clinical Oncology DispensaryOncologist, Head of the Department of Chemotherapy
Olga V Khrupalo
Diagnostic Clinical Center №1District Specialist, the Division No.3
Elena V Tiuvinova
City Polyclinic №201Oncologist
Viktor M Sherstnev
Oncologic Dispensary №5Cand. Sci. (Med.), Head of the Department of Chemotherapy
Igor' S Chernov
Oncologic Dispensary №5Cand. Sci. (Med.), Oncologist
Dzheims Dzh Kolokolov
City Polyclinic №195Oncologist
Elena A Gaisina
"Medical City"Cand. Sci. (Med.), Head of the Department of Chemotherapy
Natal'ia V Levchenko
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical CareCand. Sci. (Med.), Head of Day Patient Department
Viacheslav A Chubenko
Saint Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical CareCand. Sci. (Med.), Head of the Department of Chemotherapy
Anton Iu Povyshev
District Clinical HospitalChemotherapist
Inna V Iudina
Clinical Oncologic DispensaryHead of Day Patient Department
Liudmila V Vorotilina
Clinical Oncologic DispensaryChemotherapist of Day Patient Department
Tat'iana V Andreeva
Smolensk Regional Oncological DispensaryHead of the Department of Chemotherapy
Garnik S Tumanian
Primorsky Regional Oncology CenterOncologist
Anton E Koziakov
Novosibirsk Regional Clinical Oncologic DispensaryHead of the Department of Oncology No.2
Liudmila A Gil'mutdinova
Regional Clinical Center of OncologyHead of the Mammalogy Center
Mikhail A Osipov
Leningrad Regional Oncological DispensaryOncologist of Day Patient Department
Alina S Shatokhina
Clinical Oncology Dispensary №1Head of the Department of Outpatient Chemotherapy and Day Patient Department
Alena A Vazhenina
Medical Center "Sunrise Clinic"Cand. Sci. (Med.), General Director
Angelina S Chichkanova
Privolzhskii District Medical CenterHead of the Department of Oncology
Vladimir I Vladimirov
Pyatigorsk Interdistrict Oncologic DispensaryMD, Ph.D, Head of the Day Patient Department
Aleksandr N Ivanov
Republican Clinical Oncologic DispensaryOncologist
Anna S Belokhvostova
Republican Oncology CenterHead of Day Patient Department
Elena M Cherniakova
Republican Oncology CenterHead of Day Patient Department
Elena A Tul'china
Bryansk Regional Oncological CenterHead of the Department of Chemotherapy
Svetlana A Maklashova
Bryansk Regional Oncological CenterResident Doctor of the Department of Chemotherapy
Oksana N Shkodenko
Stavropol Regional Clinical Oncology DispensaryHead of the Department of Chemotherapy No.2
Iuliia V Kostalanova
Samara Regional Clinical Oncology DispensaryCand. Sci. (Med.), Head of the Department of Chemotherapy No.2
Anna V Tarasova
Tolyatti City Clinical Hospital №5Head of the Department of Chemotherapy No.1
Evgeniia S Kuz'mina
Salekhard District Clinical HospitalOncologist, Head of the Department of Oncology
References
- Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М.: МНИОИ им. П.А.Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.
- Savci-Heijink C.D, Halfwerk H, Hooijer G.K et al. Retrospective analysis of metastatic behaviour of breast cancer subtypes. Breast Cancer Res Treat 2015; 150 (3): 547-57. doi: 10.1007/s10549-015-3352-0
- Lebert J.M, Lester R, Powell E et al. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 2018; 25 (Suppl. 1): S142-S150. doi: 10.3747/co.25.3954
- Стенина М.Б., Жукова Л.Г., Королева И.А. и др. Практические рекомендации по лекарственному лечению инвазивного рака молочной железы. Злокачественные опухоли. Практические рекомендации RUSSCO #3s2. 2018; 8: 113-44.
- Cardoso F, Costa A, Senkus E et al. ESO-ESMO 3nd international consensus guidelines for advanced breast cancer (ABC3). Breast 2017; 31: 244-59.
- Колядина И.В., Поддубная И.В. Роль капецитабина и эрибулина в лечении метастатического HER2-негативного распространенного рака молочной железы. Современная онкология. 2018; 20 (3): 26-9.
- Инструкция по медицинскому применению препарата ХалавенR (РУ ЛП-001782 от 28.07.2012, с изменениями от 29.11.2018).
- Cortes J, Schoffski P, Littlefield B. Multiple modes of action of eribulin mesylate: Emerging data and clinical implication. Cancer Treat Rev 2018; 70: 190-8.
- Funahashi Y, Okamoto K, Adachi Y et al. Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci 2014; 105 (10): 1334-42.
- Ozawa Y, Okamoto K, Adachi M et al. Supression of metastasis and improvement of drug distribution by eribulin mesylate. Presented at: EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, November 18-21, 2014, Spain, Barcelona.
- De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13: 97-110.
- Liu X, Fan D. The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links. Curr Pharm Des 2015; 21: 1279-91.
- Yoshida T, Ozawa Y, Kimura T et al. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer 2014; 110: 1497-505.
- Dezső Z, Oestreicher J, Weaver A et al. Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells. PLoS One 2014; 9: e106131.
- Kurebayashi J, Kanomata N, Yamashita T et al. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells. Breast Cancer 2016; 23: 425-36.
- Cortes J, O’Shaughnessy J, Loesch D et al. Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a Phase 3 open-label randomised study. Lancet 2011; 377 (9769): 914-23.
- Kaufman P.A, Cortes J, Awada A et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and taxan. J Clin Oncol 2015; 33 (6): 594-601.
- Twelves C, Awada A, Cortes J et al. Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer 2016; 10: 77-84.
- Pivot X., Seock Ah Im, Guo M, Marm F. Subgroup analysis of patients with HER2 negative metastatic breast cancer in the second line setting from a phase 3, open label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer 2018; 25 (3): 370-4. doi: 10.1007/s12282-017-0826-4
- Болотина Л.В., Манзюк Л.В., Горбунова В.А. и др. Результаты первого ретроспективного анализа данных по применению эрибулина у пациентов с метастатическим раком молочной железы в условиях реальной клинической практики в России. Современная Онкология. 2016; 18 (3): 27-32.
- Манзюк Л.В., Коваленко Е.И., Горбунова В.А. и др. Эффективность и безопасность эрибулина при различных подтипах рака молочной железы: данные из реальной клинической практики в России. Злокачественные опухоли. 2017; 7 (3): 44-54.